我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中(未招募)
1
33.3%
招募中
2
66.7%
暂无批准数据
- TRiCares has successfully implanted its Topaz transcatheter tricuspid heart valve replacement (TTVR) system in the first patients in a U.S. Early Feasibility Study. - The TRICURE EFS (NCT06506942) will evaluate the safety and performance of the Topaz TTVR system in adults with severe tricuspid regurgitation at increased operative risk. - The initial implantations were performed at Piedmont Heart Institute and the Medical University of South Carolina, with both patients recovering well post-procedure. - TRiCares is also progressing with its TRICURE EU Pivotal study in Europe, marking significant steps toward regulatory approvals for the Topaz valve.